Product name: Cannabigerol
Synonym name: CBG
Catalogue No.: BPF8287
Cas No.: 25654-31-3
Formula: C₂₁H₃₂O₂
Mol Weight: 316.485
Botanical Source: Hemp
Type of Compound: Phenols

Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle

The product could be supplied from milligrams to grams.
Inquire for bulk scale.

For Reference Standard and R&D, Not for Human Use Directly.

Review of Cannabigerol (CBG)

Cannabigerol (CBG) is a type of cannabinoid obtained from the cannabis plant. It's often referred to as the mother of all cannabinoids. This is because other cannabinoids are derived from cannabigerolic acid (CBGA), an acidic form of CBG.

Cannabigerol (CBG) is found in smaller quantities than other cannabinoids in cannabis plants. In most strains of the plant, only 1% of CBG can be found compared to 20 to 25% of CBD or 25 to 30% of THC.

Cannabigerol (CBG) is processed by the body's endocannabinoid system. The endocannabinoid system is made up of molecules and receptors in our bodies that are responsible for keeping our bodies in an optimal state regardless of what’s going on in our external environment.

In our bodies, Cannabigerol (CBG) imitates endocannabinoids, the natural compounds our body makes. 

Like CBD, CBG has been used to combat pain without having the intoxicating effect of cannabinoids like THC. 

Research shows that Cannabigerol (CBG) can also have therapeutic effects. However, human studies on this are sparse and more research needs to be done in this area.

Some promising animal studies show that Cannabigerol (CBG) might ultimately be found useful for the following therapeutic benefits listed below.

Cannabigerol is a non-psychotropic phytocannabinoid which has a low affinity for the CB1 and CB2 receptors but affects the endocannabinoid system by inhibiting anandamide uptake. It also acts as a potent alpha2+adrenoceptor agonist (EC50= 0.2 nM)2. In vitro, cannabigerol was shown to reduce cell loss viability and inhibit apoptosis in motor neurons as well as reducing inflammatory cytokine levels in neural cultures. In in vivo experimental animal models it was shown to antagonize the 5-HT1A receptor (Kb= 51.9 nM), inhibit vas deferens contractions via a2 adrenoceptor mediation as well as improve motor deficits and prevent neurotoxicity and the upregulation of proinflammatory markers on striatal neurons in mice models.